{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:23:25Z","timestamp":1792041805299,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,3]]},"DOI":"10.7759\/cureus.72952","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T07:16:32Z","timestamp":1730704592000},"source":"Crossref","is-referenced-by-count":2,"title":["Nilotinib as an Independent Risk Factor for Stroke by Accelerated Atherosclerosis"],"prefix":"10.7759","author":[{"given":"Shamira","family":"Sibal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Patankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar","family":"Raut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger KJ","year":"2011","unstructured":"Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, Valent P. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011, 86:533-9. 10.1002\/ajh.22037","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.245","article-title":"Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site","volume":"31","author":"Hadzijusufovic E","year":"2017","unstructured":"Hadzijusufovic E, Albrecht-Schgoer K, Huber K, et al.. Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia. 2017, 31:2388-97. 10.1038\/leu.2017.245","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus A","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, et al.. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016, 30:1044-54. 10.1038\/leu.2016.5","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian HM","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, et al.. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021, 35:440-53. 10.1038\/s41375-020-01111-2","journal-title":"Leukemia"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.058776","article-title":"Clinical cardiac safety profile of nilotinib","volume":"97","author":"Kim TD","year":"2012","unstructured":"Kim TD, le Coutre P, Schwarz M, et al.. Clinical cardiac safety profile of nilotinib. Haematologica. 2012, 97:883-9. 10.3324\/haematol.2011.058776","journal-title":"Haematologica"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028035","article-title":"The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia","volume":"3","author":"Minson AG","year":"2019","unstructured":"Minson AG, Cummins K, Fox L, et al.. The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia. Blood Adv. 2019, 3:1084-91. 10.1182\/bloodadvances.2018028035","journal-title":"Blood Adv"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.05.005","article-title":"The BCR\/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1\u03b2 in vascular endothelium in association with downregulation of miR-3p","volume":"58","author":"Sukegawa M","year":"2017","unstructured":"Sukegawa M, Wang X, Nishioka C, et al.. The BCR\/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1\u03b2 in vascular endothelium in association with downregulation of miR-3p. Leuk Res. 2017, 58:83-90. 10.1016\/j.leukres.2017.05.005","journal-title":"Leuk Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.119.313353","article-title":"Tyrosine kinase inhibitors in leukemia and cardiovascular events: from mechanism to patient care","volume":"40","author":"Manouchehri A","year":"2020","unstructured":"Manouchehri A, Kanu E, Mauro MJ, Aday AW, Lindner JR, Moslehi J. Tyrosine kinase inhibitors in leukemia and cardiovascular events: from mechanism to patient care. Arterioscler Thromb Vasc Biol. 2020, 40:301-8. 10.1161\/ATVBAHA.119.313353","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.104075","article-title":"Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia","volume":"99","author":"Rea D","year":"2014","unstructured":"Rea D, Mirault T, Cluzeau T, Gautier JF, Guilhot F, Dombret H, Messas E. Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica. 2014, 99:1197-203. 10.3324\/haematol.2014.104075","journal-title":"Haematologica"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4149\/BLL_2021_085","article-title":"Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib","volume":"122","author":"Petrikova L","year":"2021","unstructured":"Petrikova L, Slezakova K, Sninska Z, et al.. Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib. Bratisl Lek Listy. 2021, 122:531-7. 10.4149\/BLL_2021_085","journal-title":"Bratisl Lek Listy"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0337-0","article-title":"Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts","volume":"33","author":"Sadiq S","year":"2019","unstructured":"Sadiq S, Owen E, Foster T, et al.. Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts. Leukemia. 2019, 33:1810-4. 10.1038\/s41375-018-0337-0","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.086355","article-title":"Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia","volume":"98","author":"Racil Z","year":"2013","unstructured":"Racil Z, Razga F, Drapalova J, et al.. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica. 2013, 98:e124-6. 10.3324\/haematol.2013.086355","journal-title":"Haematologica"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.966182","article-title":"Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: a systematic review, meta-analysis and integrative bioinformatics analysis","volume":"9","author":"Li S","year":"2022","unstructured":"Li S, He J, Zhang X, Cai Y, Liu J, Nie X, Shi L. Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: a systematic review, meta-analysis and integrative bioinformatics analysis. Front Cardiovasc Med. 2022, 9:966182. 10.3389\/fcvm.2022.966182","journal-title":"Front Cardiovasc Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.04.005","article-title":"Nilotinib-associated vascular events","volume":"12","author":"Quint\u00e1s-Cardama A","year":"2012","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012, 12:337-40. 10.1016\/j.clml.2012.04.005","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105883","article-title":"Nilotinib-associated atherosclerosis presenting as multifocal intracranial stenosis and acute stroke","volume":"30","author":"Kakadia B","year":"2021","unstructured":"Kakadia B, Thakkar R, Sanborn E, Suero-Abreu GA, Jovin TG, Then R. Nilotinib-associated atherosclerosis presenting as multifocal intracranial stenosis and acute stroke. J Stroke Cerebrovasc Dis. 2021, 30:105883. 10.1016\/j.jstrokecerebrovasdis.2021.105883","journal-title":"J Stroke Cerebrovasc Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/275794-nilotinib-as-an-independent-risk-factor-for-stroke-by-accelerated-atherosclerosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T07:16:33Z","timestamp":1730704593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/275794-nilotinib-as-an-independent-risk-factor-for-stroke-by-accelerated-atherosclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,3]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.72952","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,3]]}}}